Although for the last two years tecovirimat has been recommended as a treatment for severe mpox based on activity in animal and in vitro studies, two randomised controlled human studies recently closed earlier than planned due to the lack of clinical effect.
Very limited data were included in press statements for the Palm007 and the STOMP studies in October and December 2024, respectively. However, top-line results from Palm007 were presented by Olivier Tshiani from the US National Cancer Institute at IDWeek.
Read the full report by Simon Collins, HIV i-Base here.
SEE ALSO:
Source : HIV i-Base
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.